Opus Genetics, Inc. Common Stock (IRD)

• Market cap: $82.1M
• 1 day: -0.72%
• 5 days: -1.44%
• 1 month: 14.17%
• 3 months: 45.54%
• 6 months: 45.5%
• Year to date: 8.73%
• 1 year: 5.38%
• 5 years: -82.44%
• 10 years: -99.47%
• Sector: Healthcare
• Industry: Biotechnology

About: Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

Employees: 18

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

25% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 8

12% more capital invested

Capital invested by funds: $14.7M [Q1] → $16.5M (+$1.79M) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

3.57% less ownership

Funds ownership: 32.89% [Q1] → 29.32% (-3.57%) [Q2]

7% less funds holding

Funds holding: 46 [Q1] → 43 (-3) [Q2]

22% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 9

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $5
• Avg. target: $6.5
• High target: $8

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Matthew Caufield	$8	Buy Reiterated	27 Jun 2025
LUCID CAPITAL MARKETS Dev Prasad	$5	Buy Initiated	17 Jun 2025